Сравнение

Enfuvirtid vs. Glepaglutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

159519-65-0

нет данных

Молекулярная масса

4491.88 g/mol

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Enfuvirtid	Glepaglutide
Германия	Рецептурный	Не одобрено
США	Рецептурный	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Enfuvirtid and Glepaglutide?: Enfuvirtid is classified as "Исследования (прочее)", while Glepaglutide is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Glepaglutide?: The highest available evidence level is "РКИ на людях" for Enfuvirtid and "РКИ на людях" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Glepaglutide in Germany and the United States?: Германия: Enfuvirtid — Рецептурный, Glepaglutide — Не одобрено. США: Enfuvirtid — Рецептурный, Glepaglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Glepaglutide

Германия

Рецептурный

Не одобрено

США

Рецептурный

Не одобрено

Frequently asked questions

What is the difference between Enfuvirtid and Glepaglutide?

Enfuvirtid is classified as "Исследования (прочее)", while Glepaglutide is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Glepaglutide?

The highest available evidence level is "РКИ на людях" for Enfuvirtid and "РКИ на людях" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Glepaglutide in Germany and the United States?

Германия: Enfuvirtid — Рецептурный, Glepaglutide — Не одобрено. США: Enfuvirtid — Рецептурный, Glepaglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.